vious data had suggested that umbilical cord blood would serve as an excellent source of hematopoietic stem cells.
As the use of UCBSC transplants continues to develop Umbilical cord blood stem cells (UCBSC) were used to reconstitute hematopoiesis following myeloablative thermany questions still remain unanswered about cord blood as a source of stem cells. Umbilical cord blood has many apy in a 13-month-old infant with acute nonlymphocytic leukemia (ANLL):FAB-M5 who had failed to sustain a potential advantages over other stem cell sources, including a large, accessible donor population, ease and safety of colchemotherapeutic remission. The patient's mother was 18 weeks pregnant with her second child at the time lection, decreased incidence of infectious contamination and a decreased risk of GVHD.
4
of diagnosis. Amniocentesis revealed that the fetus was HLA-haploidentical with the patient at the paternally The morbidity and mortality of allogeneic BMT is highly dependent upon the HLA compatibility of the donor and inherited allele. The umbilical cord blood was harvested and processed by Ficoll centrifugation with 100% recovthe recipient as it influences the occurrence of GVHD.
5
Increasing the HLA disparity escalates the risk of ery of 5 ؋ 10 7 mononuclear cells/kg and then cryopreserved. Two weeks after collection the cells were thawed developing acute GVHD. The majority of the UCBSCtransplanted patients reported to date have been reconstiand then infused into the patient following conditioning with total body irradiation, cyclophosphamide, and etotuted from HLA-identical donors with minimal information on patients transplanted from donors with a three antigen poside. Graft-versus-host-disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. The patient mismatch. Previous reports have cited a lower incidence of both the occurrence and severity of GVHD in UCBSC experienced clinical grade I GVHD consisting of skin involvement only that resolved within 2 weeks following transplants. 1, [6] [7] [8] [9] If this is indeed the case then it would suggest that umbilical cord blood stem cells with a greater the addition of corticosteroids. Engraftment was achieved with an absolute neutrophil count (ANC) above HLA-mismatch could be used with acceptable morbidity.
There are a number of methods that have been used in 0.5 ؋ 10 9 /l on day 16, a platelet count above 50 ؋ 10 9 /1 on day 56, platelet transfusion independence on day 32 the collection and preparation of UCBSC. 1,10-14 The ideal method for collection, processing, manipulation and storage and red blood cell transfusion independence after day 44. Three months following transplantation restriction is still to be determined. Most sources have warned that the manipulation of cord blood results in a significant fragment length polymorphisms (RFLP) revealed no discernible difference between the donor and the recipidepletion of stem cells and should be not be attempted. Cord blood cells were diluted 1:4 with TC-199 medium before centrifugation over Ficoll-Hypaque (s.g. 1.077 g/ml decreasing the WBC to 173 000/l. Induction chemotherapy was initiated as per the DCTER protocol (CCGPharmacia, Upsala, Sweden). Mononuclear cells from the interface were collected after centrifugation at 800 g for 2861) with two cycles of daunomycin, cytosine arabinoside (Ara-C), etoposide, thioguanine, dexamethasone and 30 min. The mononuclear cells were washed once in TC-199 medium and then counted on a Coulter JT cell counter weekly intrathecal Ara-C. The patient's skin lesions resolved, blood counts improved and his condition stabil-(Coulter Electronics, Hialeah, FL, USA). A small portion was set aside for flow cytometry and colony assays. ized. One month after initiation of therapy a repeat marrow aspirate was hypocellular without blasts. Two weeks later, Cord blood mononuclear cells were cryopreserved using an automated microprocessor-controlled-rate freezer. The as neutropenia was resolving, the skin lesions returned and biopsy-proven leukemic infiltration. A bone marrow at that mononuclear cells were resuspended in a TC-199 medium containing 20% cord plasma. A final concentration of 10% time revealed partial remission (M2) with 9% blasts. The CSF white count was less than 5 WBC/l but had persistent DMSO (Sigma, Irvine, UK) was added to the cold freezing medium after which the sample was immediately transblasts. The patient received cycles three and four of the same systemic chemotherapy and the intrathecal therapy ferred into a labeled cryocyte bag (Baxter Healthcare Corporation, Deerfield, IL, USA) for cryopreservation. The was intensified by adding methotrexate and hydrocortisone. Three months following diagnosis both bone marrow and cells were stored in the liquid phase of liquid nitrogen. spinal fluid were in remission (M1). Consolidation consisted of high-dose Ara-C and L-asparaginase. One month Transplantation following this therapy the marrow was again M2 (10% blasts) with clear CSF. The patient then received a 5 day
The preparative regimen included a 1200 cGy dose of total body irradiation with a 600 cGy boost to the central nercourse of mitoxantrone and etoposide. Three weeks later, on 3 January 1995, while still peripherally pancytopenic the vous system given on days −10 to −7 as 150 cGy fractions twice daily. The patient received etoposide 1000 mg/m 2 /day patient began myeloablative conditioning for a planned stem cell transplant. At the time of transplantation the by continuous infusion for 2 days on days −6 and −5 followed by cyclophosphomide 500 mg/m 2 per dose with patient weighed 10 kg.
Mesna every 8 h for nine doses on days −4 to −2. Thawed umbilical cord blood stem cells were infused on day 0. Stem cell harvest and preparation GVHD prophylaxis consisted of cyclosporine given initially as 5 mg/kg/day by continuous infusion and then The donor was a full male sibling who was 18 weeks gestation at the time of BG's diagnosis. Amniocentesis tapered from day 2 to day 119 and methotrexate on days 1 (15 mg/m 2 ), 3 (10 mg/m 2 ) and 6 (10 mg/m 2 ). Supportive revealed that the fetus was an HLA-haploidentical match (Table 1) . Umbilical cord blood stem cells were collected care included the prophylactic use of acyclovir, fluconazole, IVIG and pentamadine. G-CSF (5 g/kg/day) was used following the spontaneous vaginal delivery of the donor at 38 weeks gestation. A 300 cm 3 transfer bag spiked with a from day 7 to 19. platelet concentrate Y-tubing (Abbott Laboratories, North Chicago, IL, USA) was used for the collection. This apparColony assay atus had been primed with a 30 cm 3 mixture of TC-199 medium (Gibco BRL, Grand Island, NY, USA) and 2 ml A uniform density of 5 × 10 5 mononuclear cells/ml postFicoll and post-cryopreservation were placed in methylcellof sodium heparin (preservative free, 1000 U/ml). The ulose medium (StemCell Technologies, Vancouver, treated initially with high-dose corticosteroid therapy (10 mg/kg/day) that was tapered from day 14 to day 63. Canada) on a 24-well plate and incubated at 37°C. On day 7 and day 14 the absolute number of granulocyte-macro-
The rash was biopsied and revealed inflammation and an intranuclear inclusion suggestive of cytomegalovirus phage (CFU-GM), multipotential (CFU-GEMM) and erythroid (BFU-E) progenitor colonies were counted in (CMV). Laboratory evaluation failed to confirm CMV or other infectious processes. There were slight elevations in three wells and then recorded as the average of the wells counted (Table 2) .
liver functions (maximums: ALT = 184 IU, AST = 177 IU, bilirubin = 1.6 mg/dl). The laboratory values returned to normal within 1 week and the rash resolved within 2 weeks.
Assessment of chimerism
There was no return of these symptoms at any later time. These clinical findings were felt to be consistent with cliniDonor engraftment was assessed by RFLP analysis of peripheral blood 3 months post-transplant by Dianon Systems cal grade I GVHD according to standard grading criteria. 15 The patient did not develop chronic GVHD. There were (Stratford, CT, USA).
two brief subsequent admissions for fever. The first occurred 6 weeks post-transplant as a result of a urinary tract infection. The second occurred 3 months post-transResults plant due to an infected central line which was removed. Graft
Disease status
The cord blood volume of 180 ml was harvested and transported immediately. One hundred and fifty milliliters were At the present time the patient is 23 months post-transplant. collected while the placenta remained in utero with an He remains in complete remission with full hematopoietic additional 30 ml collected after delivery. The initial total reconstitution, no evidence of GVHD, and off all medinucleated cell count was 1 × 10 9 or 1 × 10 8 /kg. The initial cations. total mononuclear cell count was 5 × 10 8 or 5 × 10 7 /kg. Post-Ficoll total mononuclear cell count prior to cryopreservation was 5 × 10 8 or 5 × 10 7 /kg demonstrating 100% Discussion recovery ( increased risk for a poor outcome. [16] [17] [18] Transplantation The patient demonstrated engraftment with an ANC seemed the only possibility for achieving long-term surabove 0.5 × 10 9 /l on day 16. The platelet count was above vival as he had been unable to achieve a durable remission 50 × 10 9 /l on day 56. The patient received his final red despite intensive chemotherapy. At the time of myeloblood cell transfusion on day 44 and his final platelet transablation marrow recovery had not yet occurred and therefusion on day 32. fore no marrow aspiration was repeated prior to transplan-RFLP analysis done 3 months after transplant showed no tation. Allogeneic BMT has been able to provide at least a difference between donor and recipient with five inde-45% chance for long-term disease-free survival in ANLL in pendent DNA probes. complete remission. 19 In this patient who lacked a matched related donor, the use of UCBSC might theoretically be associated with lower morbidity than that of the other posHospital course sible therapeutic options of either a matched unrelated The patient remained hospitalized until day 19. On day 12 donor transplanted or a mismatched related donor transhe developed an erythematous macular rash on his face plant. Fortunately, the time of delivery of the sibling donor which then spread to his trunk and extremities. This was was appropriate for the use of UCBSC in this patient. Allogeneic BMT from an HLA-identical sibling has an estimated incidence of acute GVHD varying from 10 to Table 2 Cellularity and hematopoietic progenitor cells from Ficolled cord blood 70% depending upon the clinical setting and the prophylactic regimen used. In nonidentical scenarios the risk for
Parameter Result
developing GVHD increases in conjunction with the HLA disparity. 5 The incidence of acute GVHD in UCBSC trans- 14 found a reduced recovery of 40% with Ficoll separation, but achieved 90% GVHD direction at the DR and DQ locus and in the engraftment direction at the A locus. This patient was a 3-recovery using Percoll. Our patient demonstrated a 100% recovery with one standard Ficoll centrifugation. Although year-old with t(9,11) ALL who developed mild grade I acute and chronic GVHD that had resolved by 6 months numbers are still small, subsequent collections and processing in our laboratory with the same methods continue after transplant and achieved long-term survival. Abecasis et al 21 also performed a related UCBSC transplant misto have similar recoveries post-Ficoll. The final mononuclear cell dose of 5 × 10 7 /kg achieved in this case is well matched at the A and B locus but matched at the DR locus. The patient was a child with CML who experienced acute within the range of previous cell doses (1-33 × 10 7 /kg) used in cord blood transplantation. 6 It is just slightly below grade I GVHD, no chronic GVHD, and is surviving 14 months post-transplant. The patient reported here is the the more typical dose of 2 × 10 8 /kg generally used in conventional allogeneic transplants. 7 The ideal number of only surviving true haploidentical related UCBSC transplant in the current literature.
mononuclear cells needed for a UCBSC transplant is not known and may in fact be different from that required for This patient had clinical grade I GVHD characterized by skin involvement only, that responded quickly to treatment bone marrow and peripheral blood stem cell transplants. Previous data have suggested that engraftment may be with steroids with no known permanent sequelae. Although the data are preliminary it may be that transplantation with delayed after UCBSC transplants. 26 The cell dose used in our patient resulted in an ANC above 0.5 × 10 9 /l on day 16 greater HLA disparity may be more feasible in UCBSC transplants than in other forms of transplant. In support of and a platelet count above 50 × 10 9 /l on day 56, both near the average values of expected time to reach these parathis, Kurtzberg et al 22 recently published their results of 25 patients transplanted with unrelated cord blood stem cells. meters established in the cord blood registry patients.
6
Our experience has demonstrated several important Of these patients, 15 donor-recipient pairs were discordant at two or three HLA antigens. Acute grade III GVHD aspects relevant to UCBSC transplants. First, this represents one of the few successful related haploidentical cord blood occurred in only two of 21 evaluable patients and chronic GVHD was experienced by two patients as well.
transplants. This patient demonstrates our ability to successfully overcome two problematic areas in the early GVHD involves the recognition in an immunocompromised patient by immunocompetent donor T cells of tissue development of cord blood stem cell transplants. Previous reports of early failures in the haploidentical setting may antigens not present in the donor. 23 Risk factors for developing GVHD include sex mismatch, older age (patient have been related to advanced disease status and poor performance status at the time of transplantation. Our patient and donor), infection, HLA-mismatch, and minor antigen mismatch. 5 There are many factors that may have played had exhibited a good response with no serious medical complications at the time of transplant. Secondly, despite a role in the limited degree of GVHD in our patient. He was disparate with his donor at the non-inherited maternal the HLA disparity and using conventional GVHD prophylaxis only limited, reversible GVHD was experienced by allele making him less likely to develop GVHD than if he was disparate at the non-inherited paternal allele. This is our patient. Finally, in contrast to other experiences we were able to achieve excellent cell recovery using a Ficoll though to be due to the development of tolerance in utero to the non-inherited maternal allele. 24, 25 In this case the gender separation technique resulting in prompt engraftment after infusion of cryopreserved cells. We therefore conclude that equity of the patient and donor and the low parity of the mother also decreased the likelihood of GVHD occurring. 5 our experience encourages consideration for the use of this approach as an initial treatment option in clinically approMaternal contamination of the cord blood could result in GVHD. However, most prior studies have found minimal priate situations. or no contamination and therefore our sample was not tested. tors may contribute to diminishing the incidence and sever- been concern about the manipulation of the stem cells. 
